

Koagulase-negative Staphylokokken als multiresistente Krankheitserreger

Epidemiologie, Eigenschaften und neue Behandlungsoptionen

Ingo Stock, Brühl bei Köln

Literatur

- Adis International Limited. Ceftobiprole Medocaril: BAL5788, JNJ 30982081, JNJ30982081, RO 65-5788, RO 655788. *Drugs* 2006;7:305–22.
- Anderegg TR, Bieddenbach DJ, Jones RN, and the Quality Control Working Group. Quality control guidelines for MIC susceptibility testing of NVP-PDF 713: a novel peptide deformylase inhibitor. *Int J Antimicrob Agents* 2003;22:84–6.
- Anguera I, Del Rio A, Miro JM, Matinez-Lacasa X, et al. *Staphylococcus lugdunensis* infective endocarditis: description of 10 cases and analysis of native, prosthetic valve, and pacemaker lead endocarditis clinical profiles. *Heart* 2005;91:e10 (Online-Publikation).
- Announ N, Mattei JP, Jaoua S, Fenollar F, et al. Multifocal discitis caused by *Staphylococcus warneri*. *Joint Bone Spine* 2004;71:240–2.
- Anstead GM, Owens AD. Recent advances in the treatment of infections due to resistant *Staphylococcus aureus*. *Curr Opin Infect Dis* 2004;17:549–55.
- Bannerman TL. Gram-positive cocci. *Staphylococcus, Micrococcus, and other catalase-positive cocci that grow aerobically*. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, et al. (Hrsg.). *Manual of Clinical Microbiology* (Vol. 1). 8. Auflage. Washington DC: ASM Press, 2003.
- Bassetti M, Melica G, Di Biagio A, Righi E, et al. New antibiotics for treatment of serious infections due to antibiotic-resistant Gram-positive cocci. *Rev Med Microbiol* 2004;15:109–17.
- Bassetti M, Vitale F, Melica G, Righi E, et al. Linezolid in the treatment of Gram-positive prosthetic joint infections. *J Antimicrob Chemother* 2005;55:387–90.
- Bauer G, Berens C, Projan SJ, Hillen W. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethyl-sulphate and drug-directed Fe²⁺ cleavage of 16S rRNA. *J Antimicrob Chemother* 2004;53:592–9.
- Bellamy R, Barkham T. *Staphylococcus lugdunensis* infection sites: predominance of abscesses in the pelvic girdle region. *Clin Infect Dis* 2002;35:E32–4.
- Ben-Ami R, Navon-Venezia S, Schwartz D, Schlezinger Y, et al. Erroneous reporting of coagulase-negative staphylococci as *Kocuria* spp. by the Vitek 2 system. *J Clin Microbiol* 2005;43:1448–50.
- Bergeron J, Ammirati M, Danley D, Cols Y. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection. *Antimicrob Agents Chemother* 1996;40:2226–8.
- Betriu C, Redondo M, Boloix A, Gomez M, et al. Comparative activity of linezolid and other new agents against methicillin-resistant *Staphylococcus aureus* and teicoplanin-intermediate coagulase-negative staphylococci. *J Antimicrob Chemother* 2001;48:911–3.
- Betriu C, Rodríguez-Avial I, Sánchez BA, Gómez M, et al. In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain. *Antimicrob Agents Chemother* 2002;46:892–5.
- Bhavnani SM, Passarell JA, Owen JS, Loutit JS, et al. Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with *Staphylococcus aureus* bacteremia. *Antimicrob Agents Chemother* 2006;50:994–1000.
- Bogdanovich T, Ednie LM, Shapiro S, Appelbaum PC. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. *Antimicrob Agents Chemother* 2005;49:4210–9.
- Bogdanovich T, Esel D, Kelly LM, Bozdogan B, et al. Antistaphylococcal activity of DX-619, a new des-F86-quinolone, compared to those of other agents. *Antimicrob Agents Chemother* 2005;49:3325–33.
- Bolmstrom A, Ballow CH, Qvarnstrom A, Biedenbach DJ, et al. Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox antimicrobial potency study (ZAPS-Europe). *Clin Microbiol Infect* 2002;8:791–800.
- Bradley JS. Newer antistaphylococcal agents. *Curr Opin Pediatr* 2005;17:71–7.
- Brauers J, Kresken M, Hafner D, Shah PM, et al. Surveillance of linezolid resistance in Germany, 2001–2002. *Clin Microbiol Infect* 2005;11:39–6.
- Brodth H-R, Groll AH, Just-Nübling G. In: Stille W (Hrsg.). *Antibiotika-Therapie. Klinik und Praxis der antiinfektiösen Behandlung*. 11. Auflage. Stuttgart: Schattauer-Verlag, 2004.
- Bronstein JC, Olson SL, LeVier K, Tomilo M, et al. Purification and characterization of recombinant *Staphylococcus haemolyticus* DNA gyrase and topoisomerase IV expressed in *Escherichia coli*. *Antimicrob Agents Chemother* 2004;48:2708–11.
- Buckwalter M, Dowell JA. Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. *J Clin Pharmacol* 2005;45:1279–87.
- Buttery JP, Easton M, Pearson SR, Hogg GG. Pediatric bacteremia due to *Staphylococcus warneri*: microbiological, epidemiological, and clinical features. *J Clin Microbiol* 1997;35:2174–7.
- Caierão J, Superti S, Dias CAG, Alves d’Azevedo P. Automated systems in the identification and determination of methicillin resistance among coagulase negative staphylococci. *Mem Inst Oswaldo Cruz* 2006;101:277–9.
- Candiani G, Abbondi M, Borroni M, Romano G, et al. In vitro and in vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. *J Antimicrob Chemother* 1999;44:179–92.
- Carretto E, Barbarini D, Couto I. Identification of coagulase-negative staphylococci other than *Staphylococcus epidermidis* by automated ribotyping. *Clin Microbiol Infect* 2005;11:177–84.
- Center KJ, Reboli AC, Hubler R, Rodgers GL, et al. Decreased vancomycin susceptibility of coagulase-negative staphylococci in a neonatal intensive care unit: evidence of spread of *Staphylococcus warneri*. *J Clin Microbiol* 2003;41:4660–5.
- Chambers HF. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate *Staphylococcus aureus*. *Antimicrob Agents Chemother* 2005;49:884–8.
- Chaves F, García-Álvarez M, Sanz F, Alba C, et al. Nosocomial spread of a *Staphylococcus hominis* subsp. *novobiosepticus* strain causing sepsis in a neonatal intensive care unit. *J Clin Microbiol* 2005;43:4877–9.
- Cone LA, Sontz EM, Wilson JW, Mitruka SN. *Staphylococcus capitis* endocarditis due to a transvenous endocardial pacemaker infection: case report and review of *Staphylococcus capitis* endocarditis. *Int J Infect Dis* 2005;9:335–9.
- Costerton W, Veeh R, Shirtliff M, Pasmore M, et al. Bacterial biofilms: a common cause of persistent infections. *Science* 1999;284:1318–22.
- Credito K, Lin G, Ednie LM, Appelbaum PC. Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents. *Antimicrob Agents Chemother* 2004;48:4033–6.
- Cuevas O, Cercenado E, Vindel A, Guinea J, et al. Evolution of the antimicrobial resistance of *Staphylococcus* spp. in Spain: Five nationwide prevalence studies, 1986 to 2002. *Antimicrob Agents Chemother* 2004;48:4240–45.
- Del Alamo L, Cereda RF, Tosin I, Miranda ES, et al. Antimicrobial susceptibility of coagulase-negative staphylococci and characterization of isolates with reduced susceptibility to glycopeptides. *Diagn Microbiol Infect Dis* 1999;34:185–91.
- Deville JG, Adler S, Azimi PH, Jantusch BA, et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. *Pediatr Infect Dis J* 2003;22(Suppl):S158–63.

Dr. rer. nat. Ingo Stock, Auguste-Viktoria-Str. 29, 50321 Brühl bei Köln, E-Mail: Ingo_Stock@web.de

37. Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, et al. Survey of infections due to *Staphylococcus* species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY antimicrobial surveillance program, 1997–1999. *Clin Infect Dis* 2001;32(Suppl 2):S114–32.
38. Ebricht JR, Penugonda N, Brown W. Clinical experience with *Staphylococcus lugdunensis* bacteremia: a retrospective analysis. *Diagn Microbiol Infect Dis* 2004;48:17–21.
39. Edmiston CE Jr., Goheen MP, Seabrook GR, Johnson CP, et al. Impact of selective antimicrobial agents on staphylococcal adherence to biomedical devices. *Am J Surg* 2006;192:344–54.
40. Elliott SP, Yogev R, Shulman ST. *Staphylococcus lugdunensis*: an emerging cause of ventriculoperitoneal shunt infections. *Pediatr Neurosurg* 2001;35:128–30.
41. Emond RTD, Welsby PD, Rowland HAK (Hrsg.). *Colour Atlas of Infectious Diseases*. 4. Aufl. Edinburgh: Mosby Elsevier Science, 2003.
42. Fitzgibbon JE, Nahvi MD, Dubin DT, John JF Jr. A sequence variant of *Staphylococcus hominis* with a high prevalence of oxacillin and fluoroquinolone resistance. *Res Microbiol* 2001;152:805–10.
43. Fritsche TR, Kirby JT, Jones RN. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and Gram-positive cutaneous infections. *Diagn Microbiol Infect Dis* 2004;49:201–9.
44. Fritsche TR, Sader HS, Cleeland R, Jones RN. Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance. *Antimicrob Agents Chemother* 2005;49:1468–76.
45. Fritsche TR, Sader HS, Stillwell MG, Dowzicky MJ, et al. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000–2004). *Diagn Microbiol Infect Dis* 2005;52:195–201.
46. Fujikawa K, Chiba M, Tanaka M, Sato K. In vitro antibacterial activity of DX-619, a novel des-fluoro(6)quinolone. *Antimicrob Agents Chemother* 2005;49:3040–5.
47. Gales AC, Jones RN, Andrade SS, Pereira AS, et al. In vitro activity of tigecycline, a new glycolcycline, tested against 1,326 clinical bacterial strains isolated from Latin America. *Braz J Infect Dis* 2005;9:348–56.
48. Gales AC, Sader HS, Jones RN. Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres. *Clin Microbiol Infect* 2005;11:95–100.
49. Gander S, Hayward K, Finch R. An investigation of the antimicrobial effects of linezolid on bacterial biofilms utilizing an in vitro pharmacokinetic model. *J Antimicrob Chemother* 2002;49:301–8.
50. Gander S, Kinnaird A, Finch R. Telavancin: in vitro activity against staphylococci in a biofilm model. *J Antimicrob Chemother* 2005;56:337–43.
51. García P, Benítez R, Lam M, Salinas AM, et al. Coagulase-negative staphylococci: clinical, microbiological and molecular features to predict true bacteraemia. *J Med Microbiol* 2004;53:67–72.
52. Garduno E, Marquez I, Beteta A, Said I, et al. *Staphylococcus saprophyticus* causing native valve endocarditis. *Scand J Infect Dis* 2005;37:690–1.
53. Gaudio de Allori MC, Jure MA, Romero C, Cecilia de Castello ME. Antimicrobial resistance and production of biofilms in clinical isolates of coagulase-negative *Staphylococcus* strains. *Biol Pharm Bull* 2006;29:1592–6.
54. Geffers C, Zuschneid I, Sohr D, Ruden H, et al. Erreger nosokomialer Infektionen auf Intensivstationen: Daten des Krankenhaus-Infektions-Surveillance-Systems (KISS) aus 274 Intensivstationen. *Anesthesiol Intensivmed Notfallmed Schmerzther* 2004;39:15–9.
55. Giamarellou H, O’Riordan W, Harris H, Owen S, et al. Phase III trial comparing 3–7 days of oritavancin versus 10–14 days of vancomycin/cephalexin in the treatment of patients with complicated skin and skin structure infections (cCSSI). 43. Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 2003:Abstract L-739.
56. Glimaker M, Granert C, Krook A. Septicaemia caused by *Staphylococcus saprophyticus*. *Scand J Infect Dis* 1988;20:347–8.
57. Goldstein BP, Jones RN, Fritsche TR, Biedenbach DJ. Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections. *Diagn Microbiol Infect Dis* 2006;54:83–7.
58. Greig JM, Wood MJ. *Staphylococcus lugdunensis* vertebral osteomyelitis. *Clin Microbiol Infect* 2003;9:1139–41.
59. Gupta K, Hooton TM, Wobbe CL, Stamm WE. The prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in young women. *Int J Antimicrob Agents* 1999;11:305–8.
60. Guttman G, Garazi S, van Linthoudt D. Spondylodiscitis due to *Staphylococcus lugdunensis*. *Clin Exp Rheumatol* 2000;18:271–2.
61. Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. *Nat Rev Microbiol* 2004;2:95–108.
62. Hamza N, Ortiz J, Bonomo RA. Isolated pulmonic valve infective endocarditis: a persistent challenge. *Infection* 2004;32:170–5.
63. Harland S, Tebbs SE, Elliott TS. Evaluation of the in vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin. *J Antimicrob Chemother* 1998;41:273–6.
64. Higgins DL, Chang R, Debabov DV, Leung J, et al. Telavancin, a multi-functional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in the methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* 2005;49:1127–34.
65. Honeybourne D, Tobin C, Jevons G, Andrews J, et al. Intrapulmonary penetration of linezolid. *J Antimicrob Chemother* 2003;51:1431–4.
66. Huang CR, Lu CH, Wu JJ, Chang HW, et al. Coagulase-negative staphylococcal meningitis in adults: clinical characteristics and therapeutic outcomes. *Infection* 2005;33:56–60.
67. Huang SY, Tang RB, Chen SJ, Chung RL. Coagulase-negative staphylococcal bacteremia in critically ill children: risk factors and antimicrobial susceptibility. *J Microbiol Immunol Infect* 2003;36:51–5.
68. Huebner J, Goldmann DA. Coagulase-negative staphylococci: role as pathogens. *Annu Rev Med* 1999;50:223–36.
69. Jabes D, Candiani G, Romano G, Brunati C, et al. Efficacy of dalbavancin against methicillin-resistant *Staphylococcus aureus* in the rat granuloma pouch infection model. *Antimicrob Agents Chemother* 2004;48:1118–23.
70. Jain A, Agarwal J, Bansal S. Prevalence of methicillin-resistant, coagulase-negative staphylococci in neonatal intensive care units: findings from a tertiary care hospital in India. *J Med Microbiol* 2004;53:941–4.
71. Jauregui LE, Babazadeh S, Seltzer E, Goldberg L, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. *Clin Infect Dis* 2005;41:1407–15.
72. Jones RN, Deshpande LM, Mutnick AH, Biedenbach DJ. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. *J Antimicrob Chemother* 2002;50:915–32.
73. Jones RN, Fritsche TR, Sader HS. Antimicrobial spectrum and activity of NVP-PDF 713, a novel peptide deformylase inhibitor, tested against 1,837 recent gram-negative clinical isolates. *Diagn Microbiol Infect Dis* 2004;49:63–5.
74. Jones RN, Moet GJ, Sader HS, Fritsche TR. Potential utility of a peptide deformylase inhibitor (NVP-PDF 713) against oxazolidinone-resistant or streptogramin-resistant gram-positive organism isolates. *J Antimicrob Chemother* 2004;53:804–7.
75. Jones RN, Ross JE, Fritsche TR, Sader HS. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of potency and spectrum (ZAAPS) program assessing isolates from 16 nations. *J Antimicrob Chemother* 2006;57:279–87.
76. Jones RN, Stillwell MG, Sader HS, Fritsche TR, et al. Spectrum and potency of dalbavancin against 3,322 Gram-positive cocci isolated in the United States Surveillance Program (2004). *Diagn Microbiol Infect Dis* 2006;54:149–53.
77. Jorgensen JH, McElmeel ML, Trippy CW. In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against *Staphylococcus aureus* and coagulase-negative *Staphylococcus* species. *Antimicrob Agents Chemother* 1997;41:465–7.
78. Kaabia N, Scauarda D, Lena G, D’Rancourt M. Molecular identification of *Staphylococcus lugdunensis* in a patient with meningitis. *J Clin Microbiol* 2002;40:1824–5.
79. Kaatz GW, Seo SM, Aeschlimann JR, Houlihan HH, et al. Efficacy of LY333328 against experimental methicillin-resistant *Staphylococcus aureus* endocarditis. *Antimicrob Agents Chemother* 1998;42:981–3.
80. Kacica MA, Horgan MJ, Preston KE, Lepow M, et al. Relatedness of coagulase-negative staphylococci causing bacteraemia in low-birthweight infants. *Infect Control Hosp Epidemiol* 1994;15:658–62.
81. Kallman J, Kihlstrom E, Sjoberg L, Schollin J. Increase of staphylococci in neonatal septicaemia: a fourteen-year study. *Acta Paediatr* 1977;86:533–8.
82. Kanafani ZA. Telavancin: a new lipoglycopeptide with multiple mechanisms of action. *Expert Rev Anti Infect Ther* 2006;4:743–9.
83. Kattan HM, Flynn HW Jr., Pflugfelder SC, Robertson C, et al. Nosocomial endophthalmitis survey: current incidence of infection after surgery. *Ophthalmology* 1991;98:227–38.
84. Kauffman CA, Hertz CS, Sheagren JN. *Staphylococcus saprophyticus*: role in urinary tract infections in men. *J Urol* 1983;130:493–4.
85. King A, Phillips I, Kaniga K. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria. *J Antimicrob Chemother* 2004;53:797–803.
86. Kloos WE, George CG, Olgiate JS, Van Pelt L, et al. *Staphylococcus hominis* subsp. *novobiosepticus* subsp. nov., a novel trehalose- and N-acetyl-D-glucosamine-negative, novobiocin- and multiple-antibiotic resistant

- subspecies isolated from human blood cultures. *Int J Syst Bacteriol* 1998;48:799–812.
87. Knoblauch KJ, Von Osten H, Horstkotte MA, Rohde H, et al. Minimal attachment killing (MAK): a versatile method for susceptibility testing of attached biofilm-positive and -negative *Staphylococcus epidermidis*. *Med Microbiol Immunol (Berl)* 2002;191:107–14.
 88. Kresken M, Hafner D. Drug resistance among clinical isolates of frequently encountered bacterial species in central Europe during 1975–1995. Study Group Bacterial Resistance of the Paul-Ehrlich Society for Chemotherapy. *Infection* 1999;27(Suppl 2):S2–8.
 89. Kuter D, Tillotson GS. Hematological effects of antimicrobials: focus on the oxazolidinone linezolid. *Pharmacotherapy* 2001;21:1010–3.
 90. Labthavikul P, Petersen PJ, Bradford PA. In vitro activity of tigecycline against *Staphylococcus epidermidis* growing in an adherent-cell biofilm model. *Antimicrob Agents Chemother* 2003;47:3967–9.
 91. Lawrence SL, Roth V, Slinger R, Toye B, et al. Cloxacillin versus vancomycin for presumed late-onset sepsis in the neonatal intensive care unit and the impact upon outcome of coagulase negative staphylococcal bacteraemia: a retrospective cohort study. *BMC Ped* 2005;5:49.
 92. Lefort A, Pavie J, Garry L, Chau F, et al. Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to *Staphylococcus aureus* with or without reduced susceptibility to vancomycin and teicoplanin. *Antimicrob Agents Chemother* 2004;48:1061–4.
 93. Lopez S, Hackbarth C, Romano G, Trias J, et al. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide. *J Antimicrob Chemother* 2005;55(Suppl 2):21–4.
 94. Loutit JS, O'Riordan W, San Juan J, Mensa J, et al. Phase 2 trial comparing four regimens of oritavancin versus comparator in the treatment of patients with *Staphylococcus aureus* bacteraemia. *Clin Microbiol Infect* 2004;Abstract P541.
 95. Madrigal AG, Basuino L, Chambers HF. Efficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant *Staphylococcus aureus* or vancomycin-intermediate *Staphylococcus aureus*. *Antimicrob Agents Chemother* 2005;49:3163–5.
 96. Mateo M, Maestre JR, Aguilar L, Cafini F, et al. Genotypic versus phenotypic characterization, with respect to susceptibility and identification, of 17 clinical isolates of *Staphylococcus lugdunensis*. *J Antimicrob Chemother* 2005;56:287–91.
 97. Monsen T, Karlsson C, Wistrom J. Spread of clones of multidrug-resistant, coagulase-negative staphylococci within a university hospital. *Infect Control Hosp Epidemiol* 2005;26:76–80.
 98. Moreira BM, Daum RS. Antimicrobial resistance in staphylococci. *Pediatr Clin North Am* 1995;42:619–48.
 99. Munoz-Price LS, Lolans K, Quinn JP. Four cases of invasive methicillin-resistant *Staphylococcus aureus* (MRSA) infections treated with tigecycline. *Scand J Infect Dis* 2006;38:1081–4.
 100. Murphy T, Deitz J, Petersen P, Mikels S, et al. Therapeutic efficacy of GAR-936, a novel glycolycycline, in a rate model of experimental endocarditis. *Antimicrob Agents Chemother* 2000;44:3022–7.
 101. O'Brien TP, Maguire MG, Fink NE, Altmso E, et al. Efficacy of ofloxacin versus cefazolin and tobramycin in the therapy for bacterial keratitis. *Arch Ophthalmol* 1995;113:1257–65.
 102. Otto M. Virulence factors of the coagulase-negative staphylococci. *Frontiers Biosci* 2004;9:841–63.
 103. Patel R, Piper KE, Pouse MS, Uhl JR, et al. Frequency of isolation of *Staphylococcus lugdunensis* among staphylococcal isolates causing endocarditis: a 20-year experience. *J Clin Microbiol* 2000;38:4262–3.
 104. Paul-Ehrlich-Gesellschaft (PEG) für Chemotherapie e. V. Resistenzsituation bei klinisch wichtigen Infektionserregern gegenüber Antibiotika in Deutschland und im mitteleuropäischen Raum. PEG-Resistenzstatistiken 1998, 2001, 2004. (Online: http://www.p-e-g.org/ag_resistenz/main.htm).
 105. Persen PJ, Jacobus NV, Weiss WJ, Sum PE, et al. In vitro and in vivo antibacterial activities of a new glycolycycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). *Antimicrob Agents Chemother* 1999;43:738–44.
 106. Pinna A, Zanetti S, Sotgiu M, Sechi LA, et al. Identification and antibiotic susceptibility of coagulase negative staphylococci isolated in corneal/external infections. *Br J Ophthalmol* 1999;83:771–3.
 107. Potoski BA, Adams J, Clarke L, Shutt K, et al. Epidemiological profile of linezolid-resistant coagulase-negative staphylococci. *Clin Infect Dis* 2006;43:165–71.
 108. Raad I, Darouiche R, Vazquez J, Lentnek A, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens. *Clin Infect Dis* 2005;40:374–80.
 109. Rachid S, Ohlsen K, Witte W, Hacker J, et al. Effect of subinhibitory antibiotic concentrations on polysaccharide intercellular adhesion expression in biofilm-forming *Staphylococcus epidermidis*. *Antimicrob Agents Chemother* 2000;44:3357–63.
 110. Rao N, Regalla DM. Uncertain efficacy of daptomycin for prosthetic joint infections: a prospective case series. *Clin Orthop Relat Res* 2006;451:34–7.
 111. Rao N, Ziran BH, Hall RA, Santa ER. Successful treatment of chronic bone and joint infections with oral linezolid. *Clin Orthop Relat Res* 2004;427:67–71.
 112. Raponi G, Ghezzi MC, Gherardi G, Dicuonzo G, et al. Antimicrobial susceptibility, biochemical and genetic profiles of *Staphylococcus haemolyticus* strains isolated from the bloodstream of patients hospitalized in critical care units. *J Chemother* 2005;17:264–9.
 113. Rayner CR, Baddour LM, Birmingham MC, Norden C, et al. Linezolid in the treatment of osteomyelitis: results of a compassionate use experience. *Infection* 2004;32:8–14.
 114. Raz R, Colodner R, Kunin CM. Who are you – *Staphylococcus saprophyticus*? *Clin Infect Dis* 2005;40:896–8.
 115. Reyes N, Skinner R, Benton BM, Krause KM, et al. Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant *Staphylococcus aureus*. *J Antimicrob Chemother* 2006;58:462–6.
 116. Reyes N, Skinner R, Kaniga K, Krause KM, et al. Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* 2005;49:4344–6.
 117. Ross JE, Fritsche TR, Sader HS, Jones RN. Oxazolidinone susceptibility patterns for 2005: International report from the Zyvox® Annual Appraisal of Potency and Spectrum Study. *Int J Antimicrob Agents* 2007;29:295–301.
 118. Rupp ME, Archer GL. Coagulase-negative staphylococci: pathogens associated with medical progress. *Clin Infect Dis* 1994;19:231–45.
 119. Sader HS, Jones RN, Stilwell MG, Dowzicky MJ, et al. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. *Diagn Microbiol Infect Dis* 2005;52:181–6.
 120. Sampathkumar P, Osmon DR, Cockerill FR III. Prosthetic joint infection due to *Staphylococcus lugdunensis*. *Mayo Clin Proc* 2000;75:511–2.
 121. Saner FH, Heuer M, Rath P-M, Gensicke J, et al. Successful salvage therapy with tigecycline after linezolid failure in a liver transplant recipient with MRSA pneumonia. *Liver Transplant* 2006;12:1689–92.
 122. Schmitt-Hoffmann A, Nyman L, Roos B, Schleimer M, et al. Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. *Antimicrob Agents Chemother* 2004;48:2576–80.
 123. Schmitt-Hoffmann A, Roos B, Schleimer M, Sauer J, et al. Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. *Antimicrob Agents Chemother* 2004;48:2570–5.
 124. Schneider PF, Riley TV. *Staphylococcus saprophyticus* urinary tract infections: epidemiological data from Western Australia. *Eur J Epidemiol* 1996;12:51–4.
 125. Schwalbe RS, McIntosh AC, Qaiyumi S, Johnson JA, et al. In vitro of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci. *Antimicrob Agents Chemother* 1996;40:2416–9.
 126. Seenivasan MH, Yu VL. *Staphylococcus lugdunensis* endocarditis – the hidden peril of coagulase-negative *Staphylococcus* in blood cultures. *Eur J Clin Microbiol Infect Dis* 2003;22:489–91.
 127. Seltzer E, Dorr MB, Goldstein BP, Perry M, et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. *Clin Infect Dis* 2003;37:1298–303.
 128. Shittu AO, Lin J, Morrison D, Kolawole DO. The discovery of a multiresistant *Staphylococcus haemolyticus* clone in the hospital and community environment in south western Nigeria. *Ostomyel Wound Manage* 2005;51:67–70.
 129. Singhal R, Dhawan S, Mohanty S, Sood S, et al. Species distribution and antimicrobial susceptibility of coagulase negative staphylococci in a tertiary care hospital. *Indian J Med Res* 2006;123:569–70.
 130. Souli M, Giamarellou H. Effects of slime produced by clinical isolates of coagulase-negative staphylococci on activities of various antimicrobial agents. *Antimicrob Agents Chemother* 1998;42:939–41.
 131. Speaker MG, Milch FA, Shah MK, Eisner W, et al. Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitis. *Ophthalmology* 1991;98:639–49.
 132. Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. *J Antimicrob Chemother* 2005;55:283–8.
 133. Stefani S, Valardo PE. Epidemiology of methicillin-resistant staphylococci in Europe. *Clin Microbiol Infect* 2003;9:1179–86.
 134. Stock I, Wiedemann B, Schmitz K, Hoymann P, et al. Unveröffentlichte Daten.
 135. Stryjewski ME, Chu VH, O'Riordan WD, Warren BL, et al. Telavancin versus standard therapy for treatment of complicated skin and skin

- structure infections caused by Gram-positive bacteria: FAST 2 study. *Antimicrob Agents Chemother* 2006;50:862–7.
136. Stryjewski ME, O'Riordan WD, Lau WK, Pien FD, et al. Telavancin versus standard therapy for treatment of complicated gram-positive skin and soft tissue infections. *Clin Infect Dis* 2005;40:1601–7.
137. Stucki A, Gerber P, Acosta F, Cottagnoud M, et al. Efficacy of telavancin against penicillin-resistant pneumococci and *Staphylococcus aureus* in a rabbit meningitis model and determination of kinetic parameters. *Antimicrob Agents Chemother* 2006;50:770–3.
138. Swaney SM, Aoki H, Ganoza MC, Shinaberger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. *Antimicrob Agents Chemother* 1998;42:3251–5.
139. Vandesch F, Etienne J, Reverdy ME, Eykyn SJ. Endocarditis due to *Staphylococcus lugdunensis*: report of 11 cases and review. *Clin Infect Dis* 1993;17:871–6.
140. Van Hoovels L, De Munter P, Colaert J, Surmont I, et al. Three cases of destructive native valve endocarditis caused by *Staphylococcus lugdunensis*. *Eur J Clin Microbiol Infect Dis* 2005;24:149–52.
141. Vaudaux P, Gjinovci A, Bento M, Li D, et al. Intensive therapy with cef-tobiprole medocaril of experimental foreign-body infection by methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* 2005;49:3789–93.
142. Venkatesh MP, Placencia F, Weisman LE. Coagulase-negative staphylococcal infections in the neonate and child: an update. *Sem Pediatr Infect Dis* 2006;17:120–7.
143. Wallmark G, Arremark I, Telander B. *Staphylococcus saprophyticus*: a frequent cause of acute urinary tract infection among female outpatients. *J Infect Dis* 1978;138:791–7.
144. Ward KE, Mersfelder TL, LaPlante KL. Oritavancin – an investigational glycopeptide antibiotic. *Expert Opin Investig Drugs* 2006;15:417–29.
145. Wasilewski M, Disch D, McGill J, Harris H, et al. Equivalence of shorter course therapy with oritavancin versus vancomycin/cephalexin in complicated skin/skin structure infections (CSSI). 41. Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, 2001 (Abstract UL-18).
146. Watters AA, Jones RN, Leeds JA, Denys G, et al. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003–2004). *J Antimicrob Chemother* 2006;57:914–23.
147. Weisman LE. Coagulase-negative staphylococcal disease: emerging therapies for the neonatal and pediatric patient. *Curr Opin Infect Dis* 2004;17:237–41.
148. Wickman PA, Black JA, Moland ES, Thomson KS. In vitro activities of DX-619 and comparison quinolones against Gram-positive cocci. *Antimicrob Agents Chemother* 2006;50:2255–7.
149. Wiederhold NP, Coyle EA, Raad II, Prince RA, et al. Antibacterial activity of linezolid and vancomycin in an in vitro pharmacodynamic model of Gram-positive catheter-related bacteraemia. *J Antimicrob Chemother* 2005;55:792–5.
150. Wood CA, Sewell DL, Strausbaugh LJ. Vertebral osteomyelitis and native valve endocarditis caused by *Staphylococcus warneri*. *Diagn Microbiol Infect Dis* 1989;12:261–3.
151. Yanagihara K, Seki M, Izumikawa K, Higashiyama Y, et al. Potency of DX-619, a novel des-F(6)-quinolone, in haematogenous murine broncho-pneumonia caused by methicillin-resistant and vancomycin-intermediate *Staphylococcus aureus*. *Int J Antimicrob Agents* 2006;28:212–6.
152. Yin LY, Lazzarini L, Li F, Stevens CM, et al. Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant *Staphylococcus aureus* experimental osteomyelitis in a rabbit model. *J Antimicrob Chemother* 2005;55:995–1002.
153. Zeckel ML, Preston DA, Allen BS. In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study. *Antimicrob Agents Chemother* 2000;44:1370–4.
154. Ziebuhr W, Henning S, Eckart M, Kranzler H, et al. Nosocomial infections by *Staphylococcus epidermidis*: how a commensal bacterium turns into a pathogen. *Int J Antimicrob Agents* 2006;28(Suppl 1):S14–20.